Velocity Bioworks
Velocity Bioworks is a U.S.-based biopharma CDMO in San Antonio, Texas offering process development, analytical services, bioanalytical testing, and microbial and mammalian GMP manufacturing to funded biotech sponsors, while also serving as the internal manufacturing platform for its parent Valion Bio's Entolimod biodefense pipeline and holding an exclusive license to LarmorBio's BioScan-NMR diagnostic platform.
- Company typePrivate
- Founded2025
- HeadquartersSan Antonio, United States
- Headcount—
- GTM typeB2B
- OfferingServices
What Velocity Bioworks does
Velocity Bioworks is a U.S.-based biopharmaceutical contract development and manufacturing organization (CDMO) headquartered in San Antonio, Texas, operating as a wholly-owned subsidiary of Valion Bio, Inc. (formerly Tivic Health Systems, NASDAQ: VBIO). The company was acquired by Valion Bio in December 2025 for approximately $16.3 million via senior secured convertible note financing, and its San Antonio manufacturing facility held its grand opening on May 6, 2026. Velocity Bioworks serves funded biotech sponsors that need to translate biologic drug candidates from development into clinical-stage manufacturing, providing Process Development, Analytical Development, On-Demand Bioanalytical Testing, Microbial Clinical Manufacturing, and Mammalian Manufacturing Readiness services. The facility comprises approximately 12,600 square feet, including 4,000 sq ft of development space (2,000 sq ft process development, 2,000 sq ft analytical development) and 8,600 sq ft of GMP space (5,400 sq ft mammalian, 3,200 sq ft microbial), staffed by approximately 45 scientists and engineers.
The company operates a microbial and mammalian biologics manufacturing platform using single-use GMP fermentation, with a demonstrated 200-fold manufacturing scale-up of Entolimod at 50-liter fermentation, equivalent to approximately 1.3 million potential human doses meeting purity and potency specifications. Beyond third-party CDMO services, Velocity Bioworks acts as the internal manufacturing accelerant for its parent's Entolimod pipeline, a TLR5 agonist with FDA Fast Track and Orphan Drug designations for Acute Radiation Syndrome that is advancing toward potential U.S. Strategic National Stockpile procurement under the FDA Animal Rule pathway. Velocity Bioworks also holds an exclusive commercial development and license to LarmorBio's BioScan-NMR next-generation nuclear magnetic resonance diagnostic platform, secured at pre-institutional pricing, with the first commercial installation targeted for July 2026 at the San Antonio site, anchoring a planned advanced diagnostics service offering for both internal programs and third-party CDMO clients.
Velocity Bioworks generates revenue through three primary streams: professional services fees from third-party biotech CDMO clients (process development, analytical development, bioanalytical testing, and GMP manufacturing); non-dilutive government procurement contracts pursued by parent Valion Bio targeting BARDA, NIAID, AFRRI, and the Department of War for Strategic National Stockpile inclusion of Entolimod, including a separate engagement with Ukraine's Ministry of Health for national strategic reserve inclusion under the Regulatory Equivalence Pathway; and NIAID study funding valued at up to $7 million supporting in vivo studies required for Entolimod BLA approval under the FDA Animal Rule. Customer segments span U.S. government biodefense agencies (primary), third-party biotech CDMO sponsors, allied-nation governments (Ukraine), and planned physician-sponsored oncology supportive care studies. GTM motion combines enterprise field sales for government procurement and biotech CDMO accounts with direct clinical engagement for the planned neutropenia indication.
Velocity Bioworks firmographics
Firmographics- Name
- Velocity Bioworks
- Legal name
- Velocity Bioworks
- Website
- https://velocitybioworks.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Short description
- Velocity Bioworks is a U.S.-based biopharma CDMO in San Antonio, Texas offering process development, analytical services, bioanalytical testing, and microbial and mammalian GMP manufacturing to funded biotech sponsors, while also serving as the internal manufacturing platform for its parent Valion Bio's Entolimod biodefense pipeline and holding an exclusive license to LarmorBio's BioScan-NMR diagnostic platform.
- Ownership category
- akta.pro rank
Velocity Bioworks industry classification
Industry- Product category
- Biologics Contract Manufacturing
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Velocity Bioworks is headquartered
LocationHeadquarters
- HQ city
- San Antonio
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Velocity Bioworks business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Government Procurement (Strategic National Stockpile): Non-dilutive government contracts through BARDA, NIAID, and Department of War for Entolimod procurement into the U.S. Strategic National Stockpile, representing a potentially nine-figure revenue event if secured. Additional national stockpile opportunities with allied nations including Ukraine.
- CDMO Services (Third-Party Biologics Clients): Contract development and manufacturing organization providing process development, analytical development, bioanalytical testing, and GMP manufacturing to third-party biotech sponsors. Velocity Bioworks targets independent cash-flow-positive operations serving external clients alongside internal pipeline needs.
- NIAID Study Funding: NIAID (NIH) funding agreement valued at up to $7 million to fund in vivo studies required for Entolimod BLA approval under the FDA's Animal Rule pathway, covering study costs and co-navigating the FDA submission process.
- BioScan-NMR Diagnostic Services: Advanced diagnostics service offering anchored by the exclusive BioScan-NMR platform license, serving both internal programs and third-party CDMO clients.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Velocity Bioworks product offering
Product offeringCore offering
Velocity Bioworks is a U.S.-based biopharma contract development and manufacturing organization (CDMO) headquartered in San Antonio, Texas, providing process development, analytical development, bioanalytical testing, and phase-appropriate single-use GMP manufacturing for microbial and mammalian biologics. It operates a 50-liter fermentation scale facility capable of producing approximately 1.3 million potential human doses, serves as the internal manufacturing accelerant for its parent Valion Bio's Entolimod pipeline, and holds an exclusive commercial license to LarmorBio's BioScan-NMR next-generation nuclear magnetic resonance diagnostic platform.
Product overview
Velocity Bioworks is a U.S.-based biopharma CDMO offering an integrated suite of services comprising Process Development, Analytical Development, On-Demand Bioanalytical Testing, Microbial Clinical Manufacturing, and Mammalian Manufacturing Readiness. The company operates a 50-liter fermentation scale facility capable of producing approximately 1.3 million doses. Additionally, Velocity Bioworks holds an exclusive commercial license to LarmorBio's BioScan-NMR next-generation nuclear magnetic resonance platform, with first commercial installation targeted for July 2026, anchoring its advanced diagnostics service offering for both internal manufacturing and third-party CDMO clients.
Differentiator
Problem solved
Functional benefit
Products and services
- Process Development
Quantifiable outcome
- 200-fold manufacturing scale-up of Entolimod at 50-liter fermentation scale, producing ~1.3 million potential human doses meeting all purity and potency specifications
- +2 more outcomes
Companies that use Velocity Bioworks
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Velocity Bioworks technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Velocity Bioworks partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LarmorBiocoreVelocity Bioworks entered into an exclusive commercial development and license agreement with LarmorBio for the BioScan-NMR™ next-generation nuclear magnetic resonance platform. The first commercial installation is targeted for July 2026 at Velocity Bioworks' San Antonio facility. The agreement was secured at pre-institutional pricing ahead of LarmorBio's pending Series A financing, structuring both companies as co-dependent strategic partners rather than a conventional vendor-customer relationship. The reference site role grants Velocity Bioworks first-mover access to the platform and is expected to anchor its advanced diagnostics service offering for both internal and third-party CDMO clients.
Scale indicators8 records
Recent moves8 records
Expansion highlights7 records
Velocity Bioworks competitors and assessment
Company assessmentOthers
- Thermo Fisher Scientific (Patheon CDMO): Global CDMO services through its Patheon/bioproduction division offering biologics development and manufacturing at scale; overlaps in the same CDMO customer base but with significantly broader scale and service portfolio.
Broad incumbents
- Lonza Biologics: Global biologics CDMO leader offering process development and GMP manufacturing for microbial and mammalian biologics at scale; a direct competitor in the same CDMO category but with vastly larger capacity and a broader client base.
- Emergent BioSolutions: Biodefense-focused biopharma and CDMO with direct overlap in medical countermeasures for radiation and CBRN threats; comparable in pursuing BARDA and Strategic National Stockpile procurement as a primary revenue model.
- Catalent: Major CDMO providing biologics development, manufacturing, and fill-finish services; comparable in offering microbial and mammalian manufacturing readiness for clinical-stage programs, but at much larger scale.
- WuXi Biologics: Leading global biologics CDMO with end-to-end microbial and mammalian capabilities; directly comparable service offering though increasingly constrained by U.S. biosecurity policy for federal contracts.
- Bavarian Nordic: Vaccine and biodefense company with established BARDA procurement contracts (e.g., JYNNEOS for mpox/smallpox); comparable in pursuing non-dilutive government stockpile revenue for medical countermeasures.
Direct peers
- Statera Biopharma: Prior Entolimod rights holder from whom Valion Bio licensed the asset; comparable as a clinical-stage immunology/biotic countermeasure developer, though smaller and with different pipeline focus.
- SIGA Technologies: Biodefense company selling TPOXX into the U.S. Strategic National Stockpile; closely comparable in government stockpiling-driven business model for medical countermeasures, though focused on smallpox antiviral rather than radioprotective.
- Cytovance Biologics: U.S.-based biologics CDMO offering microbial and mammalian process development, analytical services, and GMP manufacturing for clinical-stage biotech sponsors; closely comparable in service offering and scale.
- AGC Biologics: Mid-sized biologics CDMO with microbial and mammalian manufacturing capabilities serving clinical-stage biotech sponsors; closely comparable in offering mix, though with greater geographic and scale reach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Velocity Bioworks social profiles
Digital presenceVelocity Bioworks financial estimates
Financial estimateRevenue estimate
Valuation estimate
Velocity Bioworks leadership team
Management profileNumber of profiles
Profiles1 record
Velocity Bioworks funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Velocity Bioworks M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Velocity Bioworks
What does Velocity Bioworks do?
Velocity Bioworks is a U.S.-based biopharma contract development and manufacturing organization (CDMO) headquartered in San Antonio, Texas, providing process development, analytical development, bioanalytical testing, and phase-appropriate single-use GMP manufacturing for microbial and mammalian biologics. It operates a 50-liter fermentation scale facility capable of producing approximately 1.3 million potential human doses, serves as the internal manufacturing accelerant for its parent Valion Bio's Entolimod pipeline, and holds an exclusive commercial license to LarmorBio's BioScan-NMR next-generation nuclear magnetic resonance diagnostic platform.
Is Velocity Bioworks a public or private company?
Velocity Bioworks is a private company. It is classified as corporate owned and is currently operating.
When was Velocity Bioworks founded?
Velocity Bioworks was founded in 2025.
Where is Velocity Bioworks based?
Velocity Bioworks is headquartered in San Antonio, United States, in the North America region.
How does Velocity Bioworks make money?
Four revenue lines are on record. Government Procurement (Strategic National Stockpile) is the primary driver. The others are CDMO Services (Third-Party Biologics Clients), NIAID Study Funding and bioScan-NMR Diagnostic Services.
Who are Velocity Bioworks's main competitors?
Thermo Fisher Scientific (Patheon CDMO) is listed as an others. Broad incumbents are Lonza Biologics, Emergent BioSolutions, Catalent, WuXi Biologics and Bavarian Nordic. Direct peers are Statera Biopharma, SIGA Technologies, Cytovance Biologics and AGC Biologics.
Does Velocity Bioworks have an API?
No public API is recorded for Velocity Bioworks.
What industry is Velocity Bioworks in?
Velocity Bioworks's product category is Biologics Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 541714 and its SIC code is 8731.